Key findings on new biotechnology from MyMD
MYMD-1® regulates TNF-α, an essential first line responder to acute infection, which causes trouble when overactivated.
Research shows that, at only about 146 Daltons, MYMD-1® is the first oral TNF-a regulator capable of crossing the blood-brain barrier, which should enable it to address Alzheimer’s and other brain-related diseases. Unlike other therapies, MYMD-1® selectively blocks TNF-α when it becomes overactivated in autoimmune diseases and cytokine storms, but does not block it from doing its normal job of being a first responder to any routine type of moderate infection.
Learn more about MYMD-1<sup>®</sup>